Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec, France

Moderator: Laura Piddock, Director Scientific Affairs, GARDP

In this webinar, the following aspects were presented:

  • What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
  • What are some techniques that may be used to understand the origins of resistance selection?
  • How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?

The presentation was followed by a Q&A session.

* This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019 *

This live webinar including interactive Q&A session was broadcast on 21 January 2020.

If you have questions or comments, please let us know: revive@gardp.org.